Associated Press: Foundation’s Drug Development Model Groundbreaking in Fight against Rare Disease

The Associated Press published a story this week highlighting the Cystic Fibrosis Foundation's "groundbreaking" drug development model and its role in developing CF treatments that target the root cause of the disease.

| 1 min read

The CF Foundation "funded early research on four key medicines for the genetic disease," says the story. "Those drugs and better care raised average life expectancy from 10 years in the 1960s to 41 today."

With significant funding from the Foundation, Vertex Pharmaceuticals Inc. spent 11 years screening 200,000 possibilities before finding a molecule that eventually became Kalyedco, according to the piece. In a companion video, Paul Negulescu, senior vice president for research at Vertex, says of the Foundation, "Their initial support of our research really was critical in getting us to the point where we were finding small molecules to treat the underlying defect."

Watch the video and read the full story here.

Share this article
Topics
Research
Recent news
CF Foundation Reflects on Progress Toward Equity, Racial Justice, Diversity, and Inclusion
News | 4 min read
CF Foundation Invests Up to $3.5M in Gensaic for Novel Gene Delivery Method
News | 2 min read
CF Foundation Urges Vertex Pharmaceuticals to Reverse Consequential Decision on Copay Assistance
News | 3 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.

Subscribe